ePrints

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Lookup NU author(s): Dr Nicola Hannaway, Professor Alastair GreystokeORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© 2020Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

Publication metadata

Author(s): Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, Franks KN, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley CT, Hinsley S, Krebs M, Murden G, Phillip R, Ryan AJ, Salem A, Sebag-Montefoire D, Shaw P, Twelves CJ, Walker K, Young RJ, Faivre-Finn C, Greystoke A

Publication type: Article

Publication status: Published

Journal: Clinical and Translational Radiation Oncology

Year: 2020

Volume: 25

Pages: 61-66

Print publication date: 01/11/2020

Online publication date: 21/09/2020

Acceptance date: 15/09/2020

Date deposited: 14/01/2021

ISSN (electronic): 2405-6308

Publisher: Elsevier Ireland Ltd

URL: https://doi.org/10.1016/j.ctro.2020.09.006

DOI: 10.1016/j.ctro.2020.09.006

Altmetrics

Share